These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 33776370)

  • 1. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician.
    Chebli JMF; Queiroz NSF; Damião AOMC; Chebli LA; Costa MHM; Parra RS
    World J Gastroenterol; 2021 Mar; 27(11):1022-1042. PubMed ID: 33776370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic.
    El Ouali S; Rubin DT; Cohen BL; Regueiro MD; Rieder F
    Curr Opin Gastroenterol; 2021 Jul; 37(4):313-319. PubMed ID: 33859104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group.
    Arrigo S; Alvisi P; Banzato C; Bramuzzo M; Celano R; Civitelli F; D'Arcangelo G; Dilillo A; Dipasquale V; Felici E; Fuoti M; Gatti S; Knafelz D; Lionetti P; Mario F; Marseglia A; Martelossi S; Moretti C; Norsa L; Panceri R; Renzo S; Romano C; Romeo E; Strisciuglio C; Martinelli M
    Dig Liver Dis; 2021 Mar; 53(3):283-288. PubMed ID: 33388247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future.
    Viganò C; Mulinacci G; Palermo A; Barisani D; Pirola L; Fichera M; Invernizzi P; Massironi S
    World J Gastroenterol; 2021 Sep; 27(33):5520-5535. PubMed ID: 34588749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
    Lin S; Lau LH; Chanchlani N; Kennedy NA; Ng SC
    Gut; 2022 Jul; 71(7):1426-1439. PubMed ID: 35477864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Biologics on SARS-COV-2 Disease Course When Infused Within 2 Weeks of Acquiring the Infection Among IBD Patients.
    Khan N; Patel M; Sundararajan R
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):232-233. PubMed ID: 36029967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020).
    Marín-Jiménez I; Zabana Y; Rodríguez-Lago I; Marín L; Barreiro-de Acosta M; Esteve M;
    Gastroenterol Hepatol; 2020; 43(7):408-413. PubMed ID: 32419715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition.
    Turner D; Huang Y; Martín-de-Carpi J; Aloi M; Focht G; Kang B; Zhou Y; Sanchez C; Kappelman MD; Uhlig HH; Pujol-Muncunill G; Ledder O; Lionetti P; Dias JA; Ruemmele FM; Russell RK;
    J Pediatr Gastroenterol Nutr; 2020 Jun; 70(6):727-733. PubMed ID: 32443020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory Bowel Disease Management in a Romanian Tertiary Gastroenterology Center: Challenges of the COVID-19 Pandemic.
    Vadan R; Iacob R; Costache R; Stroie T; Saizu IA; Iacob S; Gheorghe L; Diculescu M; Gheorghe C
    J Gastrointestin Liver Dis; 2020 Dec; 29(4):549-553. PubMed ID: 33331349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research.
    Nakase H; Matsumoto T; Matsuura M; Iijima H; Matsuoka K; Ohmiya N; Ishihara S; Hirai F; Wagatsuma K; Yokoyama Y; Hisamatsu T
    Digestion; 2021; 102(5):814-822. PubMed ID: 32892197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
    Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
    Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19.
    Siegel CA; Christensen B; Kornbluth A; Rosh JR; Kappelman MD; Ungaro RC; Johnson DF; Chapman S; Wohl DA; Mantzaris GJ
    J Crohns Colitis; 2020 Oct; 14(14 Suppl 3):S769-S773. PubMed ID: 33085972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?
    Scribano ML
    Dig Dis Sci; 2021 Sep; 66(9):2855-2864. PubMed ID: 33073335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 in patients with inflammatory bowel disease.
    Anikhindi SA; Kumar A; Arora A
    Expert Rev Gastroenterol Hepatol; 2020 Dec; 14(12):1187-1193. PubMed ID: 32856955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 in IBD: The experience of a single tertiary IBD center.
    Rizzello F; Calabrese C; Salice M; Calandrini L; Privitera H; Melotti L; Peruzzi G; Dussias N; Belluzzi A; Scaioli E; Decorato A; Siniscalchi A; Filippone E; Laureti S; Rottoli M; Poggioli G; Gionchetti P
    Dig Liver Dis; 2021 Mar; 53(3):271-276. PubMed ID: 33451910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre.
    Scaldaferri F; Pugliese D; Privitera G; Onali S; Lopetuso LR; Rizzatti G; Settanni CR; Pizzoferrato M; Schiavoni E; Turchini L; Amatucci V; Napolitano D; Bernabei T; Mora V; Laterza L; Papa A; Guidi L; Rapaccini GL; Gasbarrini A; Armuzzi A
    United European Gastroenterol J; 2020 Aug; 8(7):775-781. PubMed ID: 32438878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review on medical management of inflammatory bowel disease during the coronavirus disease 2019 pandemic.
    Chela H; Pasha SB; Wan XF; Ghouri YA
    J Gastroenterol Hepatol; 2021 Apr; 36(4):918-926. PubMed ID: 32876952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Pregnant Inflammatory Bowel Disease Patients During the COVID-19 Pandemic.
    De Lima-Karagiannis A; Juillerat P; Sebastian S; Pedersen N; Bar-Gil Shitrit A; van der Woude CJ
    J Crohns Colitis; 2020 Oct; 14(14 Suppl 3):S807-S814. PubMed ID: 33085970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations.
    Bekic D; Belosic Halle Z
    Scand J Gastroenterol; 2021 Jun; 56(6):656-660. PubMed ID: 33765405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.